Daniel H. Fowler, MD, senior investigator, Center for Cancer Research, National Cancer Institute, describes how T-rapa cells work.
Daniel H. Fowler, MD, senior investigator, Center for Cancer Research, National Cancer Institute, describes how T-rapa cells work.
T-rapa cells have been studied for 10-15 years in the lab, initially with experimental mouse models. In clinical trials, researchers have found that when T cells are incubated ex vivo in rapamycin (an inhibitor of mTOR), instead of dying, T cells can overcome the rapamycin effect and survive the culture system.
In this situation, the cells are being starved ex vivo, but signaling remains to keep them growing and have them emerge as healthy cells. Fowler notes that this process is somewhat paradoxical. Fowler has studied T-rapa cells in a phase II clinical trial after low-intensity allogeneic hematopoietic cell transplantation.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More